Market Overview

Merck Begins Phase II/III Study of Investigational BACE Inhibitor, MK-8931

Share:
Related MRK
Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell
Vetr Opts To Hold On Merck Despite Biotech Optimism
Visa Leads Dogs Of The Dow For November Upside, But Trails By Yield (Seeking Alpha)

From Earlier: Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced it has started a Phase II/III clinical trial designed to evaluate the safety and efficacy of MK-8931 versus placebo in patients with mild-to-moderate Alzheimer's disease. MK-8931 is Merck's novel investigational oral β-amyloid precursor protein site-cleaving enzyme (BACE) inhibitor, and is the first with this mechanism to advance to this stage of clinical research. The global, multi-center study, called EPOCH, is designed to initially evaluate the safety of MK-8931 in a cohort of 200 patients prior to advancing into a larger Phase III study.

Posted-In: News FDA

 

Related Articles (MRK)

View Comments and Join the Discussion!